We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

841% more capital invested

Capital invested by funds: $65.5M → $616M (+$550M)

173% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $3.78M

156% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 18

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

57% more funds holding

Funds holding: 49 → 77 (+28)

Holders
77
Holders Change
+28
Holders Change %
+57.14%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
17
Reduced
8
Closed
18
Calls
$10.3M
Puts
$3.78M
Net Calls
+$6.52M
Net Calls Change
+$1.49M

Top Buyers

1
QF
QVT Financial
New York
+$328M
2
RCM
RA Capital Management
Massachusetts
+$55.6M
3
AWG
Alpha Wave Global
New York
+$45.5M
4
BRC
Blue Ridge Capital
New York
+$34.8M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$33.3M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$6.22M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.95M
3
OSAM
O'Shaughnessy Asset Management
Connecticut
-$1.89M
4
NCCM
Nine Chapters Capital Management
New Jersey
-$1.11M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
QF
1
QVT Financial
New York
$280M +$328M +16,013,540 New
RCM
2
RA Capital Management
Massachusetts
$47.4M +$55.6M +2,714,800 New
AWG
3
Alpha Wave Global
New York
$38.8M +$45.5M +2,221,000 New
Franklin Resources
4
Franklin Resources
California
$34.7M +$7.15M +349,050 +21%
BRC
5
Blue Ridge Capital
New York
$29.7M +$34.8M +1,700,000 New
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$29.4M +$33.3M +1,625,221 +2,867%
Bank of Montreal
7
Bank of Montreal
Ontario, Canada
$13.2M +$550K +26,828 +4%
HM
8
HealthCor Management
New York
$12.6M +$14.7M +718,800 New
RG
9
Redmile Group
California
$12.2M +$14.3M +700,000 New
RIM
10
RS Investment Management
California
$10.1M +$11.8M +576,140 New
Primecap Management
11
Primecap Management
California
$9.58M +$11.2M +548,603 New
Goldman Sachs
12
Goldman Sachs
New York
$8.57M +$10.1M +490,782 New
Millennium Management
13
Millennium Management
New York
$6.54M +$7.68M +374,757 New
Citadel Advisors
14
Citadel Advisors
Florida
$6.29M +$7.17M +350,152 +3,376%
BNP Paribas Asset Management
15
BNP Paribas Asset Management
France
$5.83M +$6.85M +334,175 New
Invesco
16
Invesco
Georgia
$5.32M +$6.17M +301,311 +8,721%
SFM
17
Sphera Funds Management
Israel
$5.21M +$2.53M +123,486 +71%
HCMT
18
Highland Capital Management (Texas)
Texas
$5M +$5.86M +286,153 New
TCP
19
Tourbillon Capital Partners
New York
$4.8M +$5.63M +275,000 New
Axa
20
Axa
France
$4.38M +$5.14M +250,801 New
Canada Pension Plan Investment Board
21
Canada Pension Plan Investment Board
Ontario, Canada
$4.08M – – –
CS
22
Candriam SCA
Luxembourg
$3.18M +$3.73M +182,000 New
BBA
23
Baker Bros. Advisors
New York
$3.15M -$6.22M -303,574 -63%
SM
24
Sabby Management
Florida
$2.98M +$3.5M +170,821 New
Point72 Asset Management
25
Point72 Asset Management
Connecticut
$2.75M +$3.22M +157,200 New
1
2 3 4

ABUS Hedge Fund Activity: Q1 2015 in Review

77 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2015, worth a combined $616M — up 841% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ABUS positions and 18 closed out — a net gain of 28 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was QVT Financial, opening a new position worth an estimated $328M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.22M.

  • 77 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2015, up from 49 in Q4 2014.
  • Funds reported $616M of Arbutus Biopharma stock for Q1 2015, up 841% quarter-over-quarter.
  • 46 funds opened new Arbutus Biopharma positions in Q1 2015 and 18 closed out, a net change of +28 holders.
  • The largest Arbutus Biopharma buyer in Q1 2015 was QVT Financial, an estimated $328M added.
  • The largest Arbutus Biopharma seller in Q1 2015 was Baker Bros. Advisors, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2015.